Sheikh Murtuja

Sheikh Murtuja

Auto-generated profile, based on publicly available information

Sheikh Murtuja

Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra, Ranchi 835215, Jharkhand, India. Department of Pharmaceutical Technology, School of Health and Medical Sciences Adamas University, Kolkata-700126, West Bengal, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PDPankaj Dagur
Pankaj Dagur
GRGourav Rakshit
Gourav Rakshit
MSMurtuja Sheikh
Murtuja Sheikh
ABAbanish Biswas
Abanish Biswas
PJParineeta Jha
Parineeta Jha
Manik GhoshManik Ghosh
Manik Ghosh
The current global epidemic of the novel coronavirus (SARS-CoV-2) has been labeled a global public health emergency since it is causing substantial morbidity and mortality on daily basis. We need to identify an effective medication against SARS-CoV-2 because of its fast dissemination and re-emergence. This research is being carried out as part of a larger strategy to identify the most promising therapeutic targets using protein-protein interactions analysis. Mpro has been identified as one of the most important therapeutic targets. In this study, we did in-silico investigations to identify the target and further molecular docking, ADME, and toxicity prediction were done to assess the potential phyto-active antiviral compounds from Justicia adhatoda as powerful inhibitors of the Mpro of SARS-COV-2. We also investigated the capacity of these molecules to create stable interactions with the Mpro using 100 ns molecular dynamics simulation. The highest scoring compounds (taraxerol, friedelanol, anisotine, and adhatodine) were also found to exhibit excellent solubility and pharmacodynamic characteristics. We employed MMPBSA simulations to assess the stability of docked molecules in the Mpro binding site, revealing that the above compounds form the most stable complex with the Mpro. Network-based Pharmacology suggested that the selected compounds have various modes of action against SARS-CoV-2 that include immunoreaction enrichment, inflammatory reaction suppression, and more. These findings point to a promising class of drugs that should be investigated further in biochemical and cell-based studies to see their effectiveness against nCOVID-19. Communicated by Ramaswamy H. Sarma

2 April 2025 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
SMSheikh Murtuja
Sheikh Murtuja
SDSayan Das
Sayan Das
IJIndrani Das Jana
Indrani Das Jana
Deepak ShilkarDeepak Shilkar
Deepak Shilkar
GRGourav Rakshit
Gourav Rakshit
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash
Flaviviruses are the causative agents of viral hemorrhagic fever (VHF) globally and have demonstrated the capacity to result in fatal outcomes if not managed effectively. Among different types of flaviviruses, dengue (DENV) and Japanese encephalitis (JEV) viruses are the most common in tropical and subtropical countries. While vaccines have been developed and licensed for both DENV and JEV, effective treatment options remain sparse. Hence, there is a pressing need to develop small molecules that can target machineries crucial for virus replication and remain conserved across different flaviviruses, thereby could serve as a promising therapeutic option. This study outlines the synthesis of novel thiazole compounds as flavivirus NS2B–NS3 protease inhibitor and characterization of their antiviral activity against DENV and JEV. We synthesized a heterocyclic template derived from a substrate-based retrotripeptide dengue protease inhibitor, leading to 48 thiazole derivatives. Two compounds, 3aq and 3au demonstrated significant inhibition of dengue virus protease activity in vitro . Comprehensive characterization of these two compounds was conducted through biochemical assay, which revealed an uncompetitive mode of inhibition. Subsequent cell-based assays using Dengue and Japanese encephalitis viruses as representative flaviviruses revealed the potential of these compounds to block viral RNA synthesis, and viral replication exhibiting 50% inhibitory concentrations (IC50s) in the low-micromolar range. Time-course experiments unveiled that the two compounds impeded the accumulation of viral genomic RNA primarily at later stages of infection, aligning with their capacity to hinder NS2B–NS3 protease activity, polyprotein processing and viral genomic RNA replication. Finally, time of addition experiment showed the compounds remain effective even when added 9 hpi, thereby confirming their potential as promising antivirals. Together, our work presents the development and validation of flavivirus protease inhibitors with therapeutic potential against Dengue (DENV2) and Japanese encephalitis viruses.


11 March 2026 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
VBVinay N. Basavanakatti
Vinay N. Basavanakatti
MAMohammad Ali
Mohammad Ali
SMSheikh Murtuja
Sheikh Murtuja
BSBarij Nayan Sinha
Barij Nayan Sinha
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash
Objective: This study is mainly focused on the development and validation of a robust liquid chromatography–tandem mass spectrometry (LC–MS/MS) method to accurately evaluate the pharmacokinetics (PK) and metabolite profile of 19‑Monoaminothiazole (19MAT), a newly synthesized compound showing promising antiviral activity against dengue virus (DENV). The work additionally integrated in‑silico metabolite prediction tools with experimental in‑vivo metabolite identification data to comprehensively understand the metabolic fate of 19MAT. Methods: Triple‑quadrupole LC–MS/MS method was developed and validated as per ICH M10 (International council for harmonization of technical requirements for pharmaceuticals for human use) guidelines for its selectivity, linearity (1.27–1270 ng/mL), accuracy/precision, recovery, matrix effect, stability in rat plasma to quantify 19MAT to assess the PK after IV (Intravenous) and PO (Per oral) administration. Waters Xterra RP® C18 (150 mm × 4.6 mm, 5 μm) column was used in reverse phase separation of analyte and internal standard. Pharmacokinetics was assessed in Sprague Dawley rats (n=3 per dose group). BioTransformer 3.0 and SMARTCyp3.0 were used to predict metabolites, and a targeted LC–MS/MS strategy was used to identify the metabolites in plasma, urine, and feces. Results: The assay showed linear response with r² > 0.99, recovery 48–63% with acceptable matrix factors, precision ≤~11% RSD (Relative standard deviation), and stability up to 45 days (−20/−70 °C). 19MAT exhibited rapid oral absorption (Tmax ≈ 0.42 h), moderate half‑life (PO: 4.20 h), high Vd (IV: ~1977 mL/kg), and bioavailability of 23.82%. Seven metabolites were identified via plasma, urine, and feces involving hydroxylation/dihydroxylation, O-dealkylation, and glucuronidation. Conclusion: The integrated workflow establishes validated quantitation approach, appropriately identified pharmacokinetic properties, and maps metabolic pathways for 19MAT, supporting preclinical optimization.

25 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
VJVenkatesan Jayaprakash
Venkatesan Jayaprakash
MSMurtaza Sheikh
Murtaza Sheikh
JKJyothi Kumari
Jyothi Kumari
DSDharmarajan Sriram
Dharmarajan Sriram
SMShreyasi Majumdar
Shreyasi Majumdar
BSBarij Nayan Sinha
Barij Nayan Sinha
Tuberculosis, still remains a burden on the global health-care system. The year 2024 witnessed 1.23 million deaths, this is a huge number and further the disease offers various challenges as many individuals show resistance to the front-line drugs. Precisely, multi-drug resistance tuberculosis (MDR-TB) or drug-resistance tuberculosis (DR-TB) further offers serious challenge in combating and strategizing plans to alleviate the sufferings and eradicating tuberculosis. Thiazole scaffolds have been previously reported for their anti-tubercular efficiency. Keeping in mind the effectiveness of these scaffolds, in this study thiazole scaffolds were exploited for their ability to inhibit the bacteria, mycobacterium tuberculosis in the in-vitro assay. A series of 48 thiazole ring molecules were synthesized, upon screening these molecules against Mycobacterium tuberculosis H37Rv strain, it was found that two molecules 3q and 3u showed approximately two-fold better inhibitory potential than the standard drug, ethambutol and the MIC recorded was 3.97 µM and 4.40 µM respectively. While four molecules 3ag, 3ao, 3ap and 3aq showed MIC equivalent to ethambutol (7.63 µM) in the in-vitro assay. Further, seven thiazole derivatives 3m, 3s, 3t, 3as, 3at, 3au and 3av were approximately half effective for inhibition when compared to ethambutol. Two derivatives 3af and 3al showed an MIC value of 32.22 and 36.35 µM respectively. Further network pharmacology approach was applied to understand the impact of top two potent molecules in influencing the pathways in humans to combat with TB infection. Molecular docking studies of the top two molecules also established the usefulness of these molecules towards antimycobacterial efficiency and the molecules showed strong inhibition of the identified protein targets. In-silico ADMET studies also indicated towards favorable PK properties. The assay results and insights from network pharmacology and docking results combinedly indicate towards the potential of these molecules in antitubercular drug discovery venture. Further work needs to be done to explore the mechanism of inhibition in the tuberculosis bacteria

12 November 2024 in Journal of the American Nutrition Association
Verified
Journal Article
Closed access
STSmriti Tripathi
Smriti Tripathi
SMSheikh Murtuja
Sheikh Murtuja
MSMohd Usman Siddique
Mohd Usman Siddique
AAAzim Ansari
Azim Ansari
GRGourav Rakshit
Gourav Rakshit
The primary cause of memory loss is Alzheimer's disease (AD). Recent studies have shown that natural compounds like apple cider vinegar (ACV) have anti-Alzheimer's capabilities. Essential components of ACV, such as gallic acid and chlorogenic acid, may be in charge of the drug's pharmacological effects. Using molecular docking and dynamics (MD), the current work looks at the aspect of ACV that protects against AD. To study the conformational relationships and interaction mechanisms between two biological molecules (such as interactions between proteins and drugs or between proteins), MD simulation is frequently used. MD can help understand molecular structural differences between proteins and small compounds. We used acetylcholinesterase (AChE, PDB ID: 1UT6) to MD chlorogenic and gallic acids, as well as the currently prescribed medication rivastigmine (Standard medication). Furthermore, we determine the binding affinity, which may be responsible for AChE inhibition. MD simulations were performed on docked complexes of chlorogenic acid, gallic acid, and rivastigmine with receptor 1UT6 for a 300 ns trajectory to ensure the stability of docked ligand-protein complexes. The results showed that chlorogenic acid has the highest binding affinity and stability for AChE inhibition. In the docking and dynamics analysis, both techniques have predicted chlorogenic acid to be a potential constituent of ACV which shows a similar activity when compared to rivastigmine by virtue of binding affinity. These findings identify chlorogenic acid as the key component of ACV that protects against AD-related cognitive and behavioral impairments. This finding will be critical in the development of ACV-based drugs for Alzheimer's disease treatment.